In our study, the SHR in the model group had LVH and overexpression of the TGF-beta1/Ras/Erk1/2/C-Fos signaling pathway, but GJD treatment inhibited the ventricular hypertrophy, decreased the level of TGF-beta1, Ras, Erk1/2, and C-Fos, possibly due to the active constituents in GJD botanical medications. The gene discussed is MAPK3; the disease is Ventricular hypertrophy.